"We take full responsibility for what we know and know the work we are engaged in is work worth doing. Our resolve has never been stronger. I am pleased to be in a position to continue investing in what I feel is a bright future in the making at Pharmacyclics."
Pharmacyclics(R) is committed to creating and developing novel pharmaceutical products that treat serious unmet medical needs in oncology and autoimmune diseases. Its deep and broad pipeline includes four innovative drug candidates that are currently under clinical development. The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com. Pharmacyclics(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.
NOTE: Other than statements of historical fact, the statements made in
this press release about future plans for and the timing of initiation of our
clinical trials, progress of and reports of results from preclinical and
clinical studies, expected effect of our products under development, clinical
development plans and product development and corporate partnering activities
are forward-looking statements, as defined in the Private Securities
Litigation Reform Act of 1995. The words "project," "believe," "will," "may,"
"continue," "plan," "expect," "intend," "anticipate," variations of such
words, and similar expressions also identify forward-looking statements, but
their absence does not mean that the statement is not forward-looking. The
forward-looking statements are not guarantees of future performance and are
subject to risks and uncertainties that may cause actual results to differ
|SOURCE Pharmacyclics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved